Metagenomi Therapeutics (MGX) Current Leases (2023 - 2026)

Metagenomi Therapeutics (MGX) has 4 years of Current Leases data on file, last reported at $6.1 million in Q1 2026.

• Current Leases for Q1 2026 came in at $6.1 million, up 8.96% year-over-year; the trailing twelve-month figure through Mar 2026 was $6.1 million (up 8.96% YoY), and the FY2025 annual result was $6.0 million, up 7.74% from the prior year.
• Current Leases improved to $6.1 million in Q1 2026 per MGX's latest filing, from $6.0 million in the prior quarter.
• Over five years, Current Leases peaked at $6.1 million in Q1 2026 and troughed at $3.4 million in Q4 2023.
• A 4-year average of $5.2 million and a median of $5.5 million in 2025 frame the typical range for Current Leases.
• The sharpest annual moves came in 2024 and 2025: Current Leases soared 63.17% in 2024, then gained 2.08% in 2025.
• A 4-year view of Current Leases shows it stood at $3.4 million in 2023, then soared by 63.17% to $5.6 million in 2024, then climbed by 7.74% to $6.0 million in 2025, then gained by 1.33% to $6.1 million in 2026.
• Business Quant data shows MGX's Current Leases at $6.1 million in Q1 2026, $6.0 million in Q4 2025, and $5.6 million in Q3 2025.